$0.18 Earnings Per Share Expected for Catalent Inc (CTLT) This Quarter
Brokerages expect Catalent Inc (NASDAQ:CTLT) to announce earnings of $0.18 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Catalent’s earnings, with the highest EPS estimate coming in at $0.21 and the lowest estimate coming in at $0.15. Catalent reported earnings of $0.16 per share in the same quarter last year, which would indicate a positive year over year growth rate of 12.5%. The business is scheduled to issue its next quarterly earnings report before the market opens on Monday, November 6th.
On average, analysts expect that Catalent will report full-year earnings of $1.64 per share for the current fiscal year, with EPS estimates ranging from $1.58 to $1.71. For the next year, analysts anticipate that the business will report earnings of $1.86 per share, with EPS estimates ranging from $1.73 to $1.97. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Catalent.
Catalent (NASDAQ:CTLT) last released its earnings results on Monday, August 28th. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.08. The business had revenue of $616.90 million for the quarter, compared to analyst estimates of $547.48 million. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 earnings per share.
Catalent (NASDAQ:CTLT) traded up 1.93% during mid-day trading on Tuesday, reaching $42.74. The company’s stock had a trading volume of 511,717 shares. The firm’s 50 day moving average price is $41.32 and its 200 day moving average price is $36.51. Catalent has a 52 week low of $21.83 and a 52 week high of $43.39. The firm has a market capitalization of $5.35 billion and a P/E ratio of 49.13.
In other Catalent news, SVP Christine Dolan sold 1,594 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $38.75, for a total value of $61,767.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Institutional investors have recently modified their holdings of the stock. Advisor Group Inc. boosted its holdings in shares of Catalent by 1.3% in the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after buying an additional 65 shares during the last quarter. Stifel Financial Corp increased its position in Catalent by 0.9% in the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after purchasing an additional 96 shares during the last quarter. Aperio Group LLC increased its position in Catalent by 0.8% in the second quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock worth $810,000 after purchasing an additional 190 shares during the last quarter. Capstone Asset Management Co. increased its position in Catalent by 2.3% in the second quarter. Capstone Asset Management Co. now owns 10,130 shares of the company’s stock worth $356,000 after purchasing an additional 230 shares during the last quarter. Finally, People s United Financial Inc. increased its position in Catalent by 1.9% in the second quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock worth $665,000 after purchasing an additional 356 shares during the last quarter.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.